Park Hotels & Resorts Inc. logo PK - Park Hotels & Resorts Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 7
HOLD 17
SELL 2
STRONG
SELL
0
| PRICE TARGET: $15.20 DETAILS
HIGH: $18.00
LOW: $14.00
MEDIAN: $15.00
CONSENSUS: $15.20
DOWNSIDE: 3.98%

Stock News

Park Hotels & Resorts Inc. Reports Second Quarter 2026 Results

Park Hotels & Resorts Inc. Reports Second Quarter 2026 Results

TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (“Park” or the “Company”) (NYSE: PK) today announced results for the second quarter ended June 30, 2026 and provided an operational update and an update on its Non-Core hotel disposition initiative. Second Quarter Highlights Include: Comparable RevPAR was $216.87, an increase of 5.8% compared to the same period in 2025, or a 6.8% increase when excluding the Royal Palm South Beach Miami, a Tribute Portfolio Resort (“Royal Palm”), which.

Aug 06, 2026 12:15 PM businesswire.com
Park Hotels & Resorts Inc. Completes the Transformative Renovation of the Iconic Royal Palm South Beach Miami Hotel

Park Hotels & Resorts Inc. Completes the Transformative Renovation of the Iconic Royal Palm South Beach Miami Hotel

TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (“Park”) (NYSE: PK) today announced the reopening of the Royal Palm South Beach Miami, a Tribute Portfolio Resort (“Royal Palm”), following the completion of the iconic oceanfront resort's more than $100 million comprehensive renovation. "Our investment in the Royal Palm reflects Park's disciplined approach to capital allocation and our ability to create meaningful long-term shareholder value through high-return redevelopment projects.

Jul 22, 2026 12:15 PM businesswire.com
Park Hotels & Resorts: This Rally May Not Be Over

Park Hotels & Resorts: This Rally May Not Be Over

Park Hotels & Resorts remains a Buy, offering a compelling margin of safety and attractive valuation despite a 30% stock rally. Q1 results exceeded expectations, with RevPAR up 2.2% YoY, and ongoing renovations are expected to drive further improvements later on. PK's disciplined asset sales and portfolio optimization strengthen its balance sheet amid elevated leverage and support their renovations, offering a well-covered 7% dividend yield.

Jul 03, 2026 06:40 AM seekingalpha.com
Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform

Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform

BILLERICA, Mass.--(BUSINESS WIRE)--Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics”, in the "Breakthrough" special issue of Lab on a Chip. The study details a liver-centric multi-tissue chip (MTC) platform designed to capture the complex pharmacokinetic (PK) profiles of small-molecule drugs. The research marks a significant demonstration of how combinatorial NAMs en.

Jun 23, 2026 09:49 AM businesswire.com

Price Targets